ReviewAllergy, asthma & immunology research2021
Total IgE as a Marker for Chronic Spontaneous Urticaria.
Review in Allergy, asthma & immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 118 citations in OpenAlex.
- Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies.British journal of clinical pharmacology · 2025Trial
- Fenebrutinib in HNature medicine · 2021Trial
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- Murine Model of Chronic Spontaneous Urticaria-Like Skin.Allergy · 2026Article
- Exploring the Role of Gut Microbiota in Chronic Spontaneous Urticaria: Mechanisms and Potential Therapeutic Implications.Probiotics and antimicrobial proteins · 2026Review
- Bullous Wells' syndrome successfully treated with omalizumab.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Article
- Immunological Basis of Chronic Spontaneous Urticaria: Immunoglobulin E and Beyond.Yonsei medical journal · 2026Review
- Targeting Mast Cells in Chronic Spontaneous Urticaria.Current allergy and asthma reports · 2026Review
- Chronic Urticaria and Malignancy: A Review Uncovering the Common Links.Biomedicines · 2026Review
- Chronic spontaneous urticaria is associated with elevated serum zonulin levels.Scientific reports · 2026Article
- Predictive value of baseline hematological parameters for the risk of recurrence in chronic urticaria.American journal of translational research · 2026Article
- Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Association ofFrontiers in immunology · 2026Article
- Scoping review: biomarkers in chronic inducible urticaria.Frontiers in immunology · 2026Article
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- From Selective Immunoglobulin E (IgE) Deficiency to Primary Immunodeficiencies Coexisting with Chronic Spontaneous Urticaria: A Call for Immunological Survey.Journal of clinical practice and research · 2025Article
- Article
- Beyond the Skin: Exploring the Gut-Skin Axis in Chronic Spontaneous Urticaria and Other Inflammatory Skin Diseases.Biomedicines · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
Abstract
objectiveImmunoglobulin E (IgE) and its receptor, FcɛRI, importantly contribute to the pathophysiology of chronic spontaneous urticaria (CSU). Recent findings point to a possible role of total IgE as a marker of CSU disease activity, endotypes, and responses to treatment. The evidence in support of total IgE included in the diagnostic workup of patients with CSU has not yet been reviewed.
methodsPublications were searched via PubMed. The search terms used were "chronic urticaria" and "total IgE." Studies were screened by titles and abstracts, and 141 were used in the review.
resultsCSU patients frequently had elevated total IgE serum levels (up to 50%), but normal or very low total IgE levels also occurred. High total IgE may represent high disease activity, longer disease duration, high chance of responding to omalizumab treatment, quick relapse after stopping omalizumab, and lower chance of responding to cyclosporine. Low IgE, in contrast, may suggest Type IIb autoimmune CSU, poor response to treatment with omalizumab and a better chance to benefits from cyclosporine treatment. Furthermore, IgE in different CSU cohorts may have different physicochemical properties that could explain differences in treatment responses to IgE-directed therapies.
conclusionThe results of our review suggest that total IgE is a valuable marker for CSU, and we recommend its assessment in the routine diagnostic workup of CSU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.